Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KB 001 A

Drug Profile

KB 001 A

Alternative Names: Anti-PcrV mAb fragment; KB 001; KB-001A

Latest Information Update: 08 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator KaloBios Pharmaceuticals
  • Class Antibacterials; Antibodies; Monoclonal antibodies
  • Mechanism of Action PcrV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pseudomonal infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Nosocomial pneumonia; Pseudomonal infections

Most Recent Events

  • 07 Aug 2017 KaloBios Pharmaceuticals is now called Humanigen
  • 30 Jun 2015 Discontinued - Phase-I for Nosocomial pneumonia (Prevention) and Pseudomonal infections (Prevention) in USA (IV)
  • 30 Jun 2015 Discontinued - Phase-I/II for Nosocomial pneumonia (Prevention) and Pseudomonal infections (Prevention) in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top